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Recent studies suggested that Eurycoma longifolia, a herbal plant, may have the potential to treat osteoporosis in elderly male.
This study aimed to determine the eﬀects of Eurycoma longifolia supplementation on the trabecular bone microarchitecture of
orchidectomised rats (androgen-deficient osteoporosis model). Forty-eight-aged (10–12 months old) Sprague Dawley rats were
divided into six groups of sham-operated (SHAM), orchidectomised control (ORX), orchidectomised + 7mg/rat testosterone
enanthate (TEN) and orchidectomised + Eurycoma longifolia 30mg/kg (EL30), orchidectomised + Eurycoma longifolia 60mg/kg
(EL60), orchidectomised + Eurycoma longifolia 90mg/kg (EL90). Rats were euthanized following six weeks of treatment. The
left femora were used to measure the trabecular bone microarchitecture using micro-CT. Orchidectomy significantly decreased
connectivity density, trabecular bone volume, and trabecular number compared to the SHAM group. Testosterone replacement
reversed all the orchidectomy-induced changes in the micro-CT parameters. EL at 30 and 60mg/kg rat worsened the trabecular
bone connectivity density and trabecular separation parameters of orchidectomised rats. EL at 90mg/kg rat preserved the bone
volume. High dose of EL (90mg/kg) may have potential in preserving the bone microarchitecture of orchidectomised rats, but
lower doses may further worsen the osteoporotic changes.
1. Introduction
Eurycoma longifolia, known locally as “Tongkat Ali” in
Malaysia is a native herb in the Southeast Asia region, espe-
cially in Malaysia, Indonesia, Cambodia, Laos, and Vietnam
[1]. This small plant from the Simaroubaceae family can
grow up to more than 15 meters and starts to bear fruits
after 2-3 years of cultivation. Since decades ago, almost all
parts of this evergreen plant including the fruits, root, and
leaves have been sought after for its medicinal uses. However,
the most valuable component is the root which has been
more commonly used as an aphrodisiac and also to treat a
wide range of diseases, including aches, fever, malaria, sexual
insuﬃciency and glandular swelling [2–4]. The root extract
of Eurycoma longifolia has been used as herbal ingredients to
enhance blood flow and restore vitality and energy following
childbirth [5]. Due to these therapeutic values, Eurycoma
longifolia has been commercialized in various forms of health
supplement [6], and added to beverages such as coﬀee
and tea. Since decades ago, various researches have been
conducted to study and explore the active components which
are responsible for these claimed benefits. These components
are the quassinoids for example eurycomanone [3, 4, 7],
canthine-6-one alkaloids [4, 8–12], squalene derivatives [13],
and byphenylneolignans [14]. Considering the fact that this
herbal extract increased the level of testosterone in sexually
insuﬃcient individuals, there was an eﬀort to explore the role
of Eurycoma longifolia in treatment of androgen-deficiency-
related diseases. An earlier study observed the potential of
Eurycoma longifolia for the treatment of androgen-deficient
osteoporosis [15].
Osteoporosis is a systemic skeletal disease characterized
by low bone mass and microarchitectural deterioration of
bone tissue with a consequent increase in bone fragility
and increased fracture risk [16]. Male osteoporosis which
was not recognized earlier has now become an important
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public health issue. Although hip fractures involve less than
one-third of males, the mortality rate has been reported to
be 31% and 17% in males and females, respectively [17].
Osteoporotic fracture in males is associated with significant
morbidity and mortality, which have huge emotional and
financial impacts on their families and the society [18].
The treatment of choice for men with androgen-deficient
osteoporosis is testosterone-replacement therapy. This ther-
apy is recommended based on the increasing understanding
on the role of androgens in bone physiology and remodeling,
which is made evident by numerous animal and human
studies [19]. However, testosterone replacement therapy is
contraindicated in patients with prostate or breast cancer
[20]. Some physicians even perceived that testosterone
replacement therapy is associated with increased risk of
prostate cancer. A study reported that almost 35% of hypogo-
nadalmen did not receive treatment due to fear of developing
prostate cancer [21]. Another contraindication which is
worth mentioning is sleep apnoea as hypogonadal patients
may have worsening of sleep apnoea with testosterone
replacement [20]. Some may also relate testosterone replace-
ment therapy with cardiovascular disease, liver damage, and
erythrocytosis [22]. Thus, it is necessary and essential to find
an alternative treatment which not only gives protection to
the bone but at the same time possesses fewer side eﬀects
compared to the testosterone therapy.
Over the past few decades, Eurycoma longifolia has been
recognized internationally especially as an aphrodisiac and is
being used widely to enhance virility and sexual performance
in male [23, 24]. Many studies reported that this ability of
Eurycoma longifolia is associated with the increased level of
testosterone in subjects supplemented with Eurycoma longi-
folia. Recent human trials showed that Eurycoma longifolia
supplementation increased the level of testosterone, together
with the increase in the superoxide dismutase (SOD), an
antioxidant which plays an important role in slowing down
the process of aging [25–28]. Despite the documented history
of Eurycoma longifolia as a testosterone-raising herb, the
underlying mechanisms for its androgenic eﬀects remain
unclear. Shawn and Kraemer (2007) in their study suggested
that Eurycoma longifolia increased testosterone levels by
way of promoting the dissociation of testosterone from
sex-hormone-binding globulin (SHBG) [29]. This SHBG is
known to increase in aging men and causes a decrease in the
bioavailability of the active fractions of testosterone. One of
the bioactive components of Eurycoma longifolia, eurypep-
tide may enhance the biosynthesis of diﬀerent androgens,
by activating the CYP17 (17 α-hydroxylase) enzyme, thereby
boosting further the metabolism of pregninolone and 17-
OH-progesterone to dehydroepiandrosterone (DHEA) [30].
It also enhances the metabolism of progesterone and 17-OH-
progesterone to 4-androstenedione and testosterone [30].
The World Health Organization (WHO) defines osteo-
porosis as bone mineral density (BMD) value of 2.5 standard
deviations or more below the young adult women mean
value [31]. BMD measurement by dual energy X-ray absorp-
tiometry (DEXA) is currently the most common technique
for assessing the risk of osteoporosis. However, this BMD
measurement may not reflect the actual bone strength and
the risk of fragility fracture. In a prospective study involving
699 subjects, it was observed that there was an overlapping
of BMD measurements between subjects with and without
fractures [32]. In the same study, they found that the
relationship between bone mass and fracture risk was not
linear. The trabecular bone, which is predominantly aﬀected
in osteoporotic changes, is a continuous three-dimensional
network of bars and plate, with varying densities and
orientations. Several studies have suggested that connectivity
density of the trabecular bone, rather than bone density,
may be the parameter mostly aﬀected by osteoporotic
changes [33–35]. Connectivity density, with regard to bones
microarchitecture, is defined as the maximal number of
branches that can be broken before the microarchitecture
is separated into parts [36]. Apart from trabecular bone
density, histomorphometry analysis of the bone microarchi-
tecture also contributes to the prediction of fracture risk [33,
37]. However, this conventional and static two-dimensional
histomorphometry gives only limited information on bone
microarchitecture [38]. A three-dimensional, nondestructive
method of bone microarchitecture measurement pioneered
by Feldkamp et al. in 1989, has become feasible only in recent
years [39]. This microcomputed tomography (micro-CT)
imaging system gives a detailed picture of three-dimensional
bone architecture together with bone connectivity density.
This high-resolution imaging technique has become more
popular and largely applied in the field of bone research, both
in basic as well as preclinical. Thus in this study, we aimed to
observe the eﬀects of Eurycoma longifolia supplementation
on the trabecular bonemicroarchitecture in orchidectomised
rats using micro-CT.
2. Materials and Methods
2.1. Experimental Animals and Treatment. Forty-eight
Sprague Dawley rats aged 10–12 months old (300–400mg)
were divided into six groups of sham-operated (SHAM),
orchidectomised control (ORX), orchidectomised +
testosterone enanthate 7mg/rat (TEN), orchidectomised +
Eurycoma longifolia 30mg/kg (EL30), orchidectomised +
Eurycoma longifolia 60mg/kg (EL60) and orchidectomised
+ Eurycoma longifolia 90mg/kg (EL90). Eurycoma longifolia
standardized aqueous extract (EL) was given 6 days a
week via oral gavages, while testosterone was injected
intramuscularly weekly throughout the six weeks duration
of the study. The rats were housed singly in plastic cages
at room temperature with a 12-hour light-dark cycle. They
were fed with commercial rat chow (Gold Coin, Selangor,
Malaysia) and tap water ad libitum. Ethical approval was
obtained from the Universiti Kebangsaan Malaysia Animal
Ethics Committee (UKMAEC) (PP/FAR/2011/NAZRUN/22-
MARCH/362-JUNE-2011-MAY-2012).
2.2. Materials and Bone Preparation. Eurycoma longifolia
standardized aqueous extract (EL) was obtained from Phytes
Biotek Sdn, Bhd. (Shah Alam, Malaysia). The extract was in
brownish powder form and the bioactive components were
eurypeptide (22.0%), glycosaponin (41.1%) and euryco-
manone (1.6%). EL aqueous powder was dissolved in
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deionized water and given via oral gavages at doses of 30, 60,
and 90mg/kg rat weight at 9 am six days a week for six weeks
[40]. Testosterone enanthate (Jesalis Pharma, Germany)
was diluted in peanut oil and 7mg/rat was administered
via intramuscular injection once a week throughout the
study period [41]. At the end of the treatment, the rats
were euthanized by overdose of diethyl ether. Femora were
dissected and cleaned from all soft tissues. They were then
stored in 10% formalin solution until analyzed.
2.3. Micro-CT Analysis. The eﬀect of EL supplementation
on trabecular bone was assessed using micro-CT (μCT80
scanner, Scanco Medical, Switzerland). Before scanning,
measurement protocols to define parameters such as source
energy and image resolution were created. The left femur
was placed in a sample holder in a vertical direction with
the epiphyseal head facing downward. The source energy
selected for this study were 70 KVp and 114 μA with image
resolution set as “high” to obtain the best contrast between
bone and soft tissues. The trabecular bone parameters were
obtained from the distal end of the left femur. Scanning
was done at the metaphyseal area located 1.5mm below the
lowest point of the epiphyseal growth plate and extending
2.0mm in the proximal direction. This is the secondary
spongiosa area, which is rich in high-turnover trabecular
bone. Trabecular bone was chosen because its remodelling
process is more dynamic than the cortical bone [42].
2.4. Statistical Analysis. The results were expressed as mean
± standard error of the mean (SEM). The data analysis was
performed using the Statistical Package for Social Sciences
software (SPSS 19.0; SPSS, Chicago, IL, USA). The data
were tested for normality using the Kolmogorov-Smirnov
test. For normally distributed data, the statistical tests used
were the analysis of variance (ANOVA), followed by Tukey’s
Honestly Significant Diﬀerence (HSD) test. For data that
were not normally distributed, Kruskal-Wallis and Mann-
Whitney tests were used.
3. Results
There were no significant diﬀerences in body weight between
the diﬀerent groups at the beginning of the study. The body
weight increased steadily throughout the period of the study.
At the end of the study, there was a significant decrease in
the body weight of the ORX group compared to the SHAM
group (P < 0.01). The body weights of all the other groups
showed no significant diﬀerence compared to each other
(Figure 1).
In the present study, orchidectomy significantly
decreased (−37.56%, P < 0.05) the trabecular bone con-
nectivity density compared to the SHAM group (Figure 2).
In contrast, the group supplemented with testosterone
enanthate (TEN) showed an increase (+57.30%, P < 0.05)
in trabecular bone connectivity density compared to the
ORX group. Generally, the groups supplemented with EL
showed a dose-dependent increase in the trabecular bone
connectivity density. However, the bone connectivity density
of these groups were significantly lower (P < 0.05) than the
SHAM, ORX, and TEN groups. Only the group with the
highest dose of EL (EL90) showed similar trabecular bone
connectivity density compared to that of the ORX group.
Figure 3 depicts the three-dimensional image of the distal
femur metaphysis. The bone tissue chosen as the region of
interest (ROI) shown in white has been reconstructed in
three dimension to see the structural context of trabecular
bone. The loss of trabecular bone connectivity density is
apparent in the groups treated with EL (EL30, EL60 and
EL90) compared to the SHAM and TEN groups, with
associated changes in other indices of trabecular bone
microarchitecture.
Bone volume was significantly decreased in the ORX,
EL30 and EL60 groups (−24.97,−40.72, and−33.11%, resp.,
P < 0.05 for all) compared to the SHAM group (Figure 4).
EL supplementation at 90mg/kg was eﬀective in preserving
bone volume as it showed no significant diﬀerence compared
to the SHAM group.
There was a significant decrease in the trabecular number
in the ORX and all EL treated groups (−29.77, −47.23,
−47.79, and −39.91%, resp., P < 0.05 for all) compared to
the SHAM group (Figure 5). Similarly, all EL treated groups
showed significantly higher trabecular separation (+103.36,
+92.96 and +87.36%, resp., P < 0.05 for all) compared to the
SHAM group (Figure 6).
As for the trabecular thickness parameter, there were no
significant diﬀerences between the groups (Figure 7).
4. Discussion
In males, androgen deficiency caused severe loss of bone
[43], muscle, and fat mass [44, 45]. These may have
contributed to the low body weight of rats in the orchidec-
tomised control group. The body weights of rats supple-
mented with EL or receiving testosterone were preserved
from the weight loss eﬀects of orchidectomy. This may be due
to the anabolic eﬀects of testosterone and EL on the bone and
body compositions. Androgen replacement therapy on both
orchidectomised rats and hypogonadal men were found to
reverse the eﬀects of androgen deficiency on muscle mass
[45–47]. The androgenic eﬀect of EL used in this study
was supported by a five-week human study, which showed
that supplementation of water soluble extract of Eurycoma
longifolia increased muscle mass and strength [48].
In the present study, the trabecular bone microarchitec-
ture was assessed using the state of the art micro-CT. It is
capable of three-dimensional bone analysis which produces
high quality images, thus well accepted by the scientific com-
munities. A comparison study revealed that all radiographic
parameters (bone thickness and length) were significantly
correlated to the corresponding micro-CT measurements
[49]. Another study comparing three-dimensional micro-
CT and two-dimensional histomorphometry, found good
correlations between these two methods [50]. The same
study also showed an excellent correlation in the connectivity
density estimation using ConnEuler principle andmicro-CT.
As expected, the present study showed that androgen
withdrawal induced by orchidectomy had caused significant
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Figure 1: Mean body weight throughout the study. SHAM,
sham-operated; ORX, orchidectomised-control; TEN, orchidec-
tomised + 7mg/rat testosterone enanthate; EL30, orchidectomised
+ Eurycoma longifolia 30mg/kg; EL60, orchidectomised + Eurycoma
longifolia 60mg/kg; EL90, orchidectomised + Eurycoma longifolia
90mg/kg.
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Figure 2: Trabecular bone connectivity density for all the
groups after 6 weeks of treatment. SHAM, sham-operated; ORX,
orchidectomised-control; TEN, orchidectomised + 7mg/rat testos-
terone enanthate; EL30, orchidectomised + Eurycoma longifolia
30mg/kg; EL60, orchidectomised + Eurycoma longifolia 60mg/kg;
EL90, orchidectomised + Eurycoma longifolia 90mg/kg. aP < 0.05
versus SHAM, bP < 0.05 versus ORX, cP < 0.05 versus TEN.
deteriorations of the bone microarchitecture of the rats at
six weeks post-orchidectomy. These findings were supported
by Yao et al. (2005) who reported that orchidectomy caused
reduction in trabecular bone connectivity density but caused
no change in trabecular thickness [51]. Meanwhile, studies
by Yarrow et al. (2008) and Libouban et al. (2008) showed
that orchidectomy caused deterioration in all trabecular
bone microarchitectures which include trabecular bone
number, thickness and separation [41, 52]. Testosterone
replacement was able to reverse all the orchidectomy-
induced changes. This was in agreement with Yarrow et al.
(2008) which showed that testosterone administration to
orchidectomised rats significantly improved the trabecular
number, width and separation [41].
In a previous study, EL supplementation at 15mg/kg was
able to prevent bone calcium loss in orchidectomised rats,
although not as eﬀective as testosterone treatment [15]. In
the present study, higher EL doses of 30, 60, and 90mg/kg
were used to determine whether EL supplementations would
aﬀect bone microarchitecture in a dose-dependent manner.
Surprisingly, data from this study showed that EL
at doses of 30 and 60mg/kg failed to protect bone
from orchidectomy-induced changes. Supplementation of
90mg/kg EL showed some protection on the bone volume.
Meanwhile, EL doses of 30 and 60mg/kg worsened all the
bone microarchitecture indices such as the bone connectivity
density, volume, number, and separation. There is paucity
of literature on the eﬀects of Eurycoma longifolia on osteo-
porosis. However, it can be postulated that EL may directly
damage bone cells or they may be involved in the regulation
of osteoblasts and osteoclasts activities, resulting in increased
bone resorption. The standardized water extract of EL used
in this study contains eurycomanone, which was found to be
toxic to human cells [10]. However, in vitro toxicity studies
often used methanolic root extracts of Eurycoma longifolia
[10, 53], which is more potent, and thus may explain its toxic
eﬀects on human cells. Apart from eurycomanone, there are
other Eurycoma longifolia constituents, which were shown
to possess cytotoxic activities such as β carboline alkaloid,
which was active against human lung and breast-cancer cells
and canthine-6-1 alkaloid, which was active against multiple
human cancerous cells [1, 10, 54]. The toxic eﬀects of these
EL constituents may have caused the deterioration of the
bone microarchitecture found in this study.
Bone is composed of supporting cells (osteoblast and
osteocytes), remodeling cells (osteoclasts) osteoid and inor-
ganic mineral salts (hydroxyapatite). Osteoblasts synthesize
new collagenous matrix and regulate its mineralization
by concentrating calcium and phosphate, and destroying
mineralization inhibitors such as pyrophosphate and pro-
teoglycan [55, 56]. Approximately 30 to 50% of osteoblasts
become osteocytes or bone-lining cells, while the majority
of them undergo apoptosis [57]. The bone-lining cells
diﬀerentiate into osteoblasts upon exposure to parathyroid
hormone or mechanical forces [58]. The formation, acti-
vation, and resorption of osteoclasts, the bone-resorbing
cells, are regulated by the ratio of receptor activator of NF-
κβ ligand (RANKL) to osteoprotegerin (OPG), Interleukin-
1 (IL-1) and Interleukin-6 (IL-6), macrophage colony
stimulating factor (M-CSF), parathyroid hormone, 1,25-
dihydroxyvitamin D, and calcitonin [59, 60]. Both RANKL
and M-SCF are produced by osteoblasts and marrow
stromal cells, and the presence of these two cells is very
important in osteoclastogenesis [61, 62]. Bone remodeling
is the combination of bone resorption and formation by
osteoclasts and osteoblasts, respectively, to maintain bone
mass and bone strength, which can be assessed by measuring
the bone microarchitecture indices. Thus, any interruption
to these cytokines or bone cells regulating the activities
of bone resorption and bone formation, will aﬀect these
measurements. The present study showed that EL30 and
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Figure 3: Three dimensional micro-CT images of the trabecular microstructure of distal femur metaphysis. (a) sham-operated; (b)
orchidectomised-control; (c) orchidectomised + 7mg/rat testosterone enanthate; (d) orchidectomised + Eurycoma longifolia 30mg/kg; (e)
orchidectomised + Eurycoma longifolia 60mg/kg; (f) orchidectomised + Eurycoma longifolia 90mg/kg.
EL60 groups have suﬀered deterioration in the bonemicroar-
chitectures. Studies have shown that estrogen withdrawal
following ovariectomy caused deterioration of trabecular
bone microarchitecture which was related to perforation of
trabecular plates and loss of connectivity density [63–65].
In the present study, this loss of connectivity density was
reversible only with testosterone replacement but not with
EL30 and EL60 supplementations. A study by Yao et al.
(2005) on the long bone (tibia) reported that ovariectomy
caused reduction in total trabecular bone volume, connectiv-
ity, and trabecular number while trabecular thickness did not
change significantly [51]. In the current study, testosterone
depletion following orchidectomy showed similar results.
Yao et al. (2005) also reported that connectivity density of
the tibia showed contradictory findings compared to the
vertebra, partly due to the slower bone loss rate in the verte-
bra than in the tibia: there was only 20% loss of trabecular
bone in the vertebra four months postovariectomy versus
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Figure 4: Bone volume for all the groups after 6 weeks of
treatment. SHAM, sham-operated; ORX, orchidectomised control;
TEN, orchidectomised + 7mg/rat testosterone enanthate; EL30,
orchidectomised + Eurycoma longifolia 30mg/kg; EL60, orchidec-
tomised + Eurycoma longifolia 60mg/kg; EL90, orchidectomised +
Eurycoma longifolia 90mg/kg. aP < 0.05 versus SHAM, bP < 0.05
versus ORX, and cP < 0.05 versus TEN.
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Figure 5: Trabecular number for all the groups after 6 weeks of
treatment. SHAM, sham-operated; ORX, orchidectomisedcontrol;
TEN, orchidectomised + 7mg/rat testosterone enanthate; EL30,
orchidectomised + Eurycoma longifolia 30mg/kg; EL60, orchidec-
tomised + Eurycoma longifolia 60mg/kg; EL90, orchidectomised +
Eurycoma longifolia 90mg/kg. aP < 0.05 versus SHAM, bP < 0.05
versus ORX, and cP < 0.05 versus TEN.
more than 80% in the tibia [51]. In the vertebra, estrogen
depletion-induced fenestration of plates, which increased
the connectivity density, and treatments with anabolic or
antiresorptive agents filled in the fenestration, resulting in a
lower connectivity density of the bone [51].
There were no significant changes in the trabecular
thickness for all the groups. Physiologically, with the loss of
bone connectivity density, reduction in trabecular number
and widening of the trabecular separation, there would
be a compensatory trabecular thickening. This finding is
in agreement with Gasser et al. (2005) who found that
zoledronic acid (antiresorptive agent) increased trabecular
thickness without improving the bone connectivity density
[66]. Other studies have also reported compensatory increase
in the remaining trabecular following the loss of bone mass
during adulthood [67–70]. This compensatory mechanism
may account for the nonsignificant changes in the trabecular
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Figure 6: Trabecular separation for all the groups after 6 weeks of
treatment. SHAM, sham-operated; ORX, orchidectomised control;
TEN, orchidectomised + 7mg/rat testosterone enanthate; EL30,
orchidectomised + Eurycoma longifolia 30mg/kg; EL60, orchidec-
tomised + Eurycoma longifolia 60mg/kg; EL90, orchidectomised +
Eurycoma longifolia 90mg/kg. aP < 0.05 versus SHAM, bP < 0.05
versus ORX, cP < 0.05 versus TEN.
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Figure 7: Trabecular thickness for all the groups after 6 weeks of
treatment. SHAM, sham-operated; ORX, orchidectomised control;
TEN, orchidectomised + 7mg/rat testosterone enanthate; EL30,
orchidectomised + Eurycoma longifolia 30mg/kg; EL60, orchidec-
tomised + Eurycoma longifolia 60mg/kg; EL90, orchidectomised +
Eurycoma longifolia 90mg/kg. aP < 0.05 versus SHAM, bP < 0.05
versus ORX, and cP < 0.05 versus TEN.
thickness for the orchidectomised rats seen in the present
study.
Supplementation of EL at 90mg/kg showed preservation
in the trabecular volume although it was less eﬀective than
testosterone. As mentioned earlier, EL may have indirectly
improved bone volume by increasing the testosterone level.
Although there is paucity in literature on the eﬀects of EL
on bone microarchitecture, there are many studies on the
relationship between testosterone and bone metabolism and
structure. A study on hypogonadal men given testosterone
treatment showed significant increases in trabecular bone
volume fraction and thickness after 24 months of treat-
ment [71]. Meanwhile, another study on supraphysiolog-
ical administration of testosterone enanthate also showed
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improvements on the trabecular number and width, and
reduction in trabecular separation [41].
Although the exact mechanisms are still unclear, it was
suggested that Eurycoma longifolia increased free testosterone
level by enhancing the dissociation of testosterone from
SHBG [29]. Eurycoma longifolia has also been shown to
enhance the metabolism of diﬀerent types of androgens,
thus increasing the levels of more biologically active andro-
gens, testosterone, and DHEA [30]. The latter mechanism
may be supported by recent human trials on Eurycoma
longifolia supplementation, which showed that water extract
of Eurycoma longifolia increased the total testosterone and
DHEA levels [25–28, 72]. In animal studies involving rats
and mice, both the water and ethanolic extracts of Eurycoma
longifolia were found to increase the sexual motivation,
performance, and frequency of sexual activity [2, 23].
In one of the studies, it was shown that at 800mg/kg,
Eurycoma longifolia promoted the growth of the reproductive
organs (seminal vesicles and ventral prostate) in male rats
[23]. These eﬀects resembled those induced by testosterone
administration [73]. Testosterone may exert its eﬀects
directly via activation of the androgen receptor (AR) found
on bone skeletal surfaces or indirectly via aromatization of
androgens (testosterone) to estrogen [19]. Thus, the increase
in androgens may play an important role in maintaining the
bone volume of the rats supplemented with 90mg/kg dose of
EL.
5. Conclusion
In conclusion, EL supplementations at the dose of 30
and 60mg/kg deteriorated the bone microarchitecture of
orchidectomised rats. At higher dose of 90mg/kg, EL
supplementation was only able to preserve bone volume.
Further studies are required to determine if low dose of EL
is toxic to bone cells, and if higher dose than 90mg/kg would
provide better protection to bone microarchitecture.
Acknowledgment
The authors would like to thank Mrs Sinar Suriya Muham-
mad, Mrs Farhana Mohd Fozi, Ms Juliana Abdul Hamid,
Ms Nurul Hafizah Abas, and Mr Fadhlullah Zuhair from the
Department of Pharmacology for their technical assistance.
The authors would also like to thank Mrs Zarina Jaafar from
School of Dental Sciences, USM for her help during the
micro-CT analysis. This study wasmade possible through the
grant UKM-FF-03-FRGS0047-2009 provided by the Faculty
of Medicine UKM.
References
[1] P. C. Kuo, L. S. Shi, A. G. Damu et al., “Cytotoxic and
antimalarial β-carboline alkaloids from the roots of Eurycoma
longifolia,” Journal of Natural Products, vol. 66, no. 10, pp.
1324–1327, 2003.
[2] H. H. Ang, K. L. Lee, and M. Kiyoshi, “Eurycoma longifolia
Jack enhances sexual motivation in middle-aged male mice,”
Journal of Basic and Clinical Physiology and Pharmacology, vol.
14, no. 3, pp. 301–308, 2003.
[3] M. Darise, H. Kohda, K. Mizutani, and O. Tanaka, “Euryco-
manone and eurycomanol, quassinoids from the roots of
Eurycoma longifolia,” Phytochemistry, vol. 21, no. 8, pp. 2091–
2093, 1982.
[4] P. C. Kuo, A. G. Damu, K. H. Lee, and T. S. Wu, “Cytotoxic
and antimalarial constituents from the roots of Eurycoma
longifolia,” Bioorganic and Medicinal Chemistry, vol. 12, no. 3,
pp. 537–544, 2004.
[5] Z. Ismail, N. Ismail, and J. Lassa, Malaysian Herbal Mono-
graph, Malaysian Monograph Committee, Kuala Lumpur,
malaysia, 1999.
[6] A. S. A. Rahman, M. M. S. Yap, A. Y. M. Shakaﬀ et al., “A
microcontroller-based taste sensing system for the verification
of Eurycoma longifolia,” Sensors and Actuators, B, vol. 101, no.
1-2, pp. 191–198, 2004.
[7] K. L. Chan, C. Y. Choo, H. Morita, and H. Itokawa,
“High performance liquid chromatography in phytochemical
analysis of Eurycoma longifolia,” Planta Medica, vol. 64, no. 8,
pp. 741–745, 1998.
[8] K. L. Chan, C. Y. Choo, N. R. Abdullah, and Z. Ismail,
“Antiplasmodial studies of Eurycoma longifolia Jack using
the lactate dehydrogenase assay of Plasmodium falciparum,”
Journal of Ethnopharmacology, vol. 92, no. 2-3, pp. 223–227,
2004.
[9] C. Y. Choo and K. L. Chan, “High performance liquid chro-
matography analysis of canthinone alkaloids from Eurycoma
longifolia,” Planta Medica, vol. 68, no. 4, pp. 382–384, 2002.
[10] L. B. S. Kardono, C. K. Angerhofer, S. Tsauri, K. Padmawinata,
J.M. Pezzuto, and A. D. Kinghorn, “Cytotoxic and antimalarial
constituents of the roots of Eurycoma longifolia,” Journal of
Natural Products, vol. 54, no. 5, pp. 1360–1367, 1991.
[11] K. Mitsunaga, K. Koike, T. Tanaka et al., “Canthin-6-one
alkaloids from Eurycoma longifolia,” Phytochemistry, vol. 35,
no. 3, pp. 799–802, 1994.
[12] S. Tan, K. H. Yuen, and K. L. Chan, “HPLC analysis of plasma
9-methoxycanthin-6-one from Eurycoma longifolia and its
application in a bioavailability/pharmacokinetic study,” Planta
Medica, vol. 68, no. 4, pp. 355–358, 2002.
[13] H. Morita, E. Kishi, K. Takeya, H. Itokawa, and Y. Iitaka,
“Squalene derivatives from Eurycoma longifolia,” Phytochem-
istry, vol. 34, no. 3, pp. 765–771, 1993.
[14] H. Morita, E. Kishi, K. Takeya, and H. Itokawa, “Biphenylne-
olignans from wood of Eurycoma longifolia,” Phytochemistry,
vol. 31, no. 11, pp. 3993–3995, 1992.
[15] A. N. Shuid, M. F. Abu Bakar, T. A. Abdul Shukor, N.
Muhammad, N. Mohamed, and I. N. Soelaiman, “The anti-
osteoporotic eﬀect of Eurycoma longifolia in aged orchidec-
tomised rat model,” The Aging Male, vol. 14, no. 3, pp. 150–
154, 2011.
[16] National Osteoporosis Foundation, Clinician’s Guide to Pre-
vention and Treatment of Osteoporosis, National Osteoporosis
Foundation, Washington, DC, USA, 2010.
[17] S. Amin and D. T. Felson, “Osteoporosis in men,” Rheumatic
Disease Clinics of North America, vol. 27, no. 1, pp. 19–47,
2001.
[18] O. Johnell, J. Kanis, and G. Gullberg, “Mortality, morbidity,
and assessment of fracture risk in male osteoporosis,” Calcified
Tissue International, vol. 69, no. 4, pp. 182–184, 2001.
[19] D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg,
R. Bouillon, and C. Ohlsson, “Androgens and bone,” Endocrine
Reviews, vol. 25, no. 3, pp. 389–425, 2004.
8 Evidence-Based Complementary and Alternative Medicine
[20] S. Bhasin, G. R. Cunningham, F. J. Hayes et al., “Testosterone
therapy in adult men with androgen deficiency syndromes:
an endocrine society clinical practice guideline,” Journal of
Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp.
1995–2010, 2006.
[21] L. J. Gooren, H. M. Behre, F. Saad, A. Frank, and S. Schwerdt,
“Diagnosing and treating testosterone deficiency in diﬀerent
parts of the world. Results from global market research,” Aging
Male, vol. 10, no. 4, pp. 173–181, 2007.
[22] E. L. Rhoden and A. Morgentaler, “Risks of testosterone-
replacement therapy and recommendations for monitoring,”
New England Journal of Medicine, vol. 350, no. 5, pp. 482–492,
2004.
[23] H. H. Ang, H. S. Cheang, and A. P. M. Yusof, “Eﬀects of
Eurycoma longifolia Jack (Tongkat Ali) on the initiation of
sexual performance of inexperienced castrated male rats,”
Experimental Animals, vol. 49, no. 1, pp. 35–38, 2000.
[24] H. H. Ang, K. L. Lee, and M. Kiyoshi, “Sexual arousal
in sexually sluggish old male rats after oral administration
of Eurycoma longifolia Jack,” Journal of Basic and Clinical
Physiology and Pharmacology, vol. 15, no. 3-4, pp. 303–309,
2004.
[25] M. I. Tambi, “Glycoprotein water-soluble extract of Eurycoma
longifolia Jack as a health supplement inmanagement of health
aging in aged men,” in Proceedings of the 3rdWorld Congress on
the Aging male, Berlin, Germany, February 2002.
[26] M. I. Tambi, “Water soluble extract of Eurycoma longifolia
in enhancing testosterone in males,” in Proceeding of the
International Trade Show and Conference, Supply Side West, the
Venetian, Las Vegas, Nev, USA, October 2003.
[27] M. I. Tambi, “Standardized water soluble extract of Eurycoma
longifolia (LJ100) on men’s health,” in Proceedings of the 8th
International Congress of Andrology, Seoul, Korea, June 2005.
[28] M. I. Tambi, “Standardized water soluble extract of Eurycoma
longifolia Jack LJ100 maintains healthy aging in men,” in
Proceedings of the 5th World Congress on the Aging Male,
Salzburg, Austria, February 2006.
[29] T. Shawn and W. Kraemer, The Cortisol Connection, Hunter
House, Calif, USA, 2007.
[30] J. M. Ali and J. M. Saad, Biochemical eﬀects of Eurycoma
longifolia Jack on the sexual behavior, fertility, sex hormone
and glycolysis [Dissertation], Department of Biochemistry,
University of Malaya, Malaysia, 1993.
[31] J. A. Kanis, L. J. Melton, C. Christiansen, C. C. Johnston, and
N. Khaltaev, “The diagnosis of osteoporosis,” Journal of Bone
and Mineral Research, vol. 9, no. 8, pp. 1137–1141, 1994.
[32] R. D. Wasnich, P. D. Ross, J. W. Davis, and J. M. Vogel, “A
comparison of single and multi-site BMC measurements for
assessment of spine fracture probability,” Journal of Nuclear
Medicine, vol. 30, no. 7, pp. 1166–1171, 1989.
[33] M. Kleerekoper, A. R. Villanueva, and J. Stanciu, “The
role of three-dimensional trabecular microstructure in the
pathogenesis of vertebral compression fractures,” Calcified
Tissue International, vol. 37, no. 6, pp. 594–597, 1985.
[34] L. Mosekilde, “Consequences of the remodelling process
for vertebral trabecular bone structure: a scanning electron
microscopy study (uncoupling of unloaded structures),” Bone
and Mineral, vol. 10, no. 1, pp. 13–35, 1990.
[35] A. M. Parfitt, “Trabecular bone architecture in the patho-
genesis and prevention of fracture,” The American Journal of
Medicine, vol. 82, no. 1, pp. 68–72, 1987.
[36] A. Odgaard and H. J. G. Gundersen, “Quantification of
connectivity in cancellous bone, with special emphasis on 3-
D reconstructions,” Bone, vol. 14, no. 2, pp. 173–182, 1993.
[37] A. M. Parfitt, “Implications of architecture for the pathogen-
esis and prevention of vertebral fracture,” Bone, vol. 13, no. 2,
pp. S41–S47, 1992.
[38] A. M. Parfitt, “The stereologic basis of bone histomorphom-
etry, theory of quantitative microscopy and reconstruction of
the third dimension,” in Bone Histo-Morphometry: Technique
and Interpretations, R. Recker, Ed., pp. 53–87, CRC Press, Boca
Raton, Fla, USA, 1983.
[39] L. A. Feldkamp, S. A. Goldstein, A. M. Parfitt, G. Jesion,
and M. Kleerekoper, “The direct examination of three-
dimensional bone architecture in vitro by computed tomog-
raphy,” Journal of Bone and Mineral Research, vol. 4, no. 1, pp.
3–11, 1989.
[40] N. A. Wahab, N. M. Mokhtar, W. N. H. A. Halim, and S. Das,
“The eﬀect of Eurycoma longifolia Jack on spermatogenesis in
estrogen-treated rats,” Clinics, vol. 65, no. 1, pp. 93–98, 2010.
[41] J. F. Yarrow, C. F. Conover, A. V. Purandare et al., “Supraphys-
iological testosterone enanthate administration prevents bone
loss and augments bone strength in gonadectomized male and
female rats,”American Journal of Physiology. Endocrinology and
Metabolism, vol. 295, no. 5, pp. E1213–E1222, 2008.
[42] P. A. J. Baldock, H. A. Morris, A. G. Need, R. J. Moore, and
T. C. Durbridge, “Variation in the short-term changes in bone
cell activity in three regions of the distal femur immediately
following ovariectomy,” Journal of Bone and Mineral Research,
vol. 13, no. 9, pp. 1451–1457, 1998.
[43] C. Meier, M. J. Seibel, and D. J. Handelsman, “Testicular
dysfunction,” in Osteoporosis in Men: The Eﬀects of Gender
on Skeletal Health, E. Orwoll, J. P. Bilezikian, and D. Vander-
schueren, Eds., pp. 423–435, Academic Press, San Diego, Calif,
USA, 2010.
[44] S. Bhasin, T.W. Storer, N. Berman et al., “Testosterone replace-
ment increases fat-free mass and muscle size in hypogonadal
men,” Journal of Clinical Endocrinology and Metabolism, vol.
82, no. 2, pp. 407–413, 1997.
[45] L. Katznelson, J. S. Finkelstein, D. A. Schoenfeld, D. I.
Rosenthal, E. J. Anderson, and A. Klibanski, “Increase in bone
density and lean body mass during testosterone administra-
tion in men with acquired hypogonadism,” Journal of Clinical
Endocrinology and Metabolism, vol. 81, no. 12, pp. 4358–4365,
1996.
[46] S. Bhasin, L. Woodhouse, R. Casaburi et al., “Testosterone
dose-response relationships in healthy young men,” American
Journal of Physiology. Endocrinology and Metabolism, vol. 281,
no. 6, pp. E1172–E1181, 2001.
[47] W. Gao, P. J. Reiser, C. C. Coss et al., “Selective androgen
receptor modulator treatment improves muscle strength and
body composition and prevents bone loss in orchidectomized
rats,” Endocrinology, vol. 146, no. 11, pp. 4887–4897, 2005.
[48] S. Hamzah and A. Yusuf, “The ergogonic eﬀects of Eurycoma
longifolia Jack: a pilot study,” British Journal of Sports Medicine,
vol. 37, pp. 464–470, 2003.
[49] A. H. Huang, C. L. Raggio, J. C. Fritton, and N. P. Cama-
cho, “Comparison of radiographic and microCT-determined
parameters in mouse bone specimens,” in 51st Annual Meeting
of the Orthopaedic Research Society, 2005.
[50] J. S. Thomsen, A. Laib, B. Koller, S. Prohaska, L. Mosekilde,
and W. Gowin, “Stereological measures of trabecular bone
structure: comparison of 3D micro computed tomography
with 2D histological sections in human proximal tibial bone
biopsies,” Journal of Microscopy, vol. 218, no. 2, pp. 171–179,
2005.
Evidence-Based Complementary and Alternative Medicine 9
[51] W. Yao, T. Hadi, Y. Jiang, J. Lotz, T. J. Wronski, and N.
E. Lane, “Basic fibroblast growth factor improves trabecular
bone connectivity and bone strength in the lumbar vertebral
body of osteopenic rats,” Osteoporosis International, vol. 16,
no. 12, pp. 1939–1947, 2005.
[52] H. Libouban, S. Blouin, M. F. Moreau, M. F. Basle´, M. Audran,
and D. Chappard, “Eﬀects of risedronate in a rat model of
osteopenia due to orchidectomy and disuse: densitometric,
histomorphometric and microtomographic studies,” Micron,
vol. 39, no. 7, pp. 998–1007, 2008.
[53] T. T. Tee and H. L. P. Azimahtol, “Induction of apoptosis by
Eurycoma longifolia Jack extracts,” Anticancer Research, vol. 25,
no. 3 B, pp. 2205–2213, 2005.
[54] M. Y. Nurhanan, L. P. A. Hawariah, A. M. Ilham, and M. A.
M. Shukri, “Cytotoxic eﬀects of the root extracts of Eurycoma
longifolia Jack,” Phytotherapy Research, vol. 19, no. 11, pp. 994–
996, 2005.
[55] H. C. Anderson, “Matrix vesicles and calcification.,” Current
Rheumatology Reports, vol. 5, no. 3, pp. 222–226, 2003.
[56] G. Karsenty, H. M. Kronenberg, and C. Settembre, “Genetic
control of bone formation,” Annual Review of Cell and
Developmental Biology, vol. 25, pp. 629–648, 2009.
[57] B. Clarke, “Normal bone anatomy and physiology.,” Clinical
journal of the American Society of Nephrology , vol. 3,
supplement 3, pp. S131–139, 2008.
[58] H. Dobnig and R. T. Turner, “Evidence that intermittent treat-
ment with parathyroid hormone increases bone formation in
adult rats by activation of bone lining cells,” Endocrinology,
vol. 136, no. 8, pp. 3632–3638, 1995.
[59] H. C. Blair and N. A. Athanasou, “Recent advances in osteo-
clast biology and pathological bone resorption,” Histology and
Histopathology, vol. 19, no. 1, pp. 189–199, 2004.
[60] W. J. Boyle, W. S. Simonet, and D. L. Lacey, “Osteoclast
diﬀerentiation and activation,” Nature, vol. 423, no. 6937, pp.
337–342, 2003.
[61] S. L. Teitelbaum and F. P. Ross, “Genetic regulation of osteo-
clast development and function,”Nature Reviews Genetics, vol.
4, no. 8, pp. 638–649, 2003.
[62] S. L. Teitelbaum, “Osteoclasts: What do they do and how do
they do it?” American Journal of Pathology, vol. 170, no. 2, pp.
427–435, 2007.
[63] N. E. Lane, J. M. Thompson, G. J. Strewler, and J. H. Kinney,
“Intermittent treatment with human parathyroid hormone
(hPTH[1-34]) increased trabecular bone volume but not
connectivity in osteopenic rats,” Journal of Bone and Mineral
Research, vol. 10, no. 10, pp. 1470–1477, 1995.
[64] N. E. Lane, D. Haupt, D. B. Kimmel, G. Mogin, and J. H.
Kinney, “Early estrogen replacement therapy reverses the rapid
bone loss of trabecular bone volume and prevents further
deterioration of connectivity in the rat,” Journal of Bone and
Mineral Research, vol. 14, no. 2, pp. 206–214, 1999.
[65] N. E. Lane, J. L. Kumer, S. Majumdar et al., “The eﬀects
of synthetic conjugated estrogens, a (Cenestin) on trabecular
bone structure and strength in the ovariectomized rat model,”
Osteoporosis International, vol. 13, no. 10, pp. 816–823, 2002.
[66] J. A. Gasser, P. Ingold, K. Grosios, A. Laib, S. Ha¨mmerle, and
B. Koller, “Noninvasive monitoring of changes in structural
cancellous bone parameters with a novel prototype micro-
CT,” Journal of Bone and Mineral Metabolism, vol. 23, no. 1,
supplement, pp. 90–96, 2005.
[67] M. Ding, J. S. Day, D. B. Burr et al., “Canine cancellous bone
microarchitecture after one year of high-dose bisphospho-
nates,” Calcified Tissue International, vol. 72, no. 6, pp. 737–
744, 2003.
[68] H. M. Frost, “On the trabecular ‘thickness’-number problem,”
Journal of Bone andMineral Research, vol. 14, no. 11, pp. 1816–
1821, 1999.
[69] G. A. Macho, R. L. Abel, and H. Schutkowski, “Age changes in
bone microstructure: do they occur uniformly?” International
Journal of Osteoarchaeology, vol. 15, no. 6, pp. 421–430, 2005.
[70] M. Stauber and R. Mu¨ller, “Age-related changes in trabecular
bone microstructures: Global and local morphometry,” Osteo-
porosis International, vol. 17, no. 4, pp. 616–626, 2006.
[71] X. H. Zhang, X. S. Liu, B. Vasilic et al., “In vivo μMRI-based
finite element and morphological analyses of tibial trabecular
bone in eugonadal and hypogonadal men before and after
testosterone treatment,” Journal of Bone and Mineral Research,
vol. 23, no. 9, pp. 1426–1434, 2008.
[72] World Health Organization, Laboratory Manual for the Exam-
ination of Human Semen Sperm-Cervical Mucus Interaction,
Cambridge University Press, New York, NY, USA, 1999.
[73] H. H. Ang and H. S. Cheang, “Eﬀects of Eurycoma longi-
folia Jack on laevator ani muscle in both uncastrated and
testosterone-stimulated castrated intact male rats,” Archives of
Pharmacal Research, vol. 24, no. 5, pp. 437–440, 2001.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
